Why the study?
Do dopaminergic agonists (piribedil and bromocriptine) reduce blood pressure and alter renal and renin-angiotensin systems in patients with mild to moderate hypertension?
Population
9 outpatients with mild and moderate hypertension
Comparison
Piribedil 50-100 mg/day orally for 8 weeks, and… vs Placebo (comparative crossover design)
Follow-up
8 weeks per treatment phase
Authors
Loading...
Does not support dopaminergic agonist use in hypertension; leaves open distinct D1 versus D2 effects on hemodynamics and renin-angiotensin axis.
Do dopaminergic agonists (piribedil and bromocriptine) reduce blood pressure and alter renal and renin-angiotensin systems in patients with mild to moderate hypertension?
Dopaminergic D1 and D2 agonists both lower blood pressure in mild-to-moderate hypertension but have divergent effects on sympathetic tone and the renin-angiotensin system.
Luchsinger et al. (1992) studied this question.
Synapse has enriched 2 closely related papers on similar clinical questions. Consider them for comparative context: